0001209191-20-034985.txt : 20200608
0001209191-20-034985.hdr.sgml : 20200608
20200608163123
ACCESSION NUMBER: 0001209191-20-034985
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200604
FILED AS OF DATE: 20200608
DATE AS OF CHANGE: 20200608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANEKO YASUNORI
CENTRAL INDEX KEY: 0001277503
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38419
FILM NUMBER: 20949488
MAIL ADDRESS:
STREET 1: 509 ROEHAMPTON
CITY: HILLS BOROUGH
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcus Biosciences, Inc.
CENTRAL INDEX KEY: 0001724521
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473898435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 694-6200
MAIL ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-04
0
0001724521
Arcus Biosciences, Inc.
RCUS
0001277503
KANEKO YASUNORI
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD
CA
94545
1
0
0
0
Common Stock
2020-06-04
4
A
0
3000
0.00
A
3000
D
Common Stock
2020-06-05
4
M
0
35000
7.99
A
38000
D
Common Stock
505050
I
By Kaneko Capital, LLC
Common Stock
252524
I
By Kaneko Investments, LLC
Common Stock
96948
I
By Trust
Stock Option (Right to Buy)
30.05
2020-06-04
4
A
0
14000
0.00
A
2030-06-03
Common Stock
14000
14000
D
Stock Option (Rights to Buy)
7.99
2020-06-05
4
M
0
35000
0.00
D
2020-06-04
2029-06-05
Common Stock
35000
0
D
Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control
Represents the exercise of options to purchase common stock by the reporting person. No shares were sold by the reporting person, and the shares received upon the exercise of such options are subject to a lock-up agreement with the underwriters for the Company's recent public offering.
The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.
/s/ Carolyn Tang, Attorney-in-Fact
2020-06-08